Suppr超能文献

[环孢素A延长治疗重症慢性荨麻疹]

[Extended cyclosporine-A--treatment for severe chronic urticaria].

作者信息

Kessel Aharon, Toubi Elias

机构信息

Division of Clinical Immunology, Bnai Zion Medical Center, Faculty of Medicine Technion, Haifa, Israel.

出版信息

Harefuah. 2006 Jun;145(6):411-4, 471.

Abstract

BACKGROUND

In patients suffering from severe chronic urticaria (CU) and in whom both antihistamine therapy and short courses of corticosteroids are needed, cyclosporine-A (CsA) should be considered. In such patients CsA given for 1-3 months (3mg/kg/d) was reported to induce in 2/3 of patients a full remission, lasting 3-6 months, and in 1/4 of patients a long-lasting full remission.

OBJECTIVE

To investigate the beneficial effect, safety and side-effects of prolonged CsA therapy in severe CU patients, in whom only short remission was previously achieved.

METHODS

Six patients (mean age 40.8 years +/- 11.9) with severe CU (disease duration 7.3 years +/- 6.2) still treated with CsA (2-3 mg/kg/d) for a period of 11.6 years +/- 4.

RESULTS

Five patients are favorably maintained on CsA treatment and do not require additional therapy. One patient required the addition of 5-10 mg/d prednisone (while continuing CsA 3 mg/kg/d) reducing the severity of urticaria. Two patients complained of mild hirsutism and peripheral neuropathy and one of a very mild diarrhea.

CONCLUSION

Prolonged treatment with CsA is beneficial for maintaining remission in severe cases of CU. It spares the need for corticosteroids and is accompanied with mild side effects. Further experience with more patients is needed in order to strengthen our findings.

摘要

背景

对于患有严重慢性荨麻疹(CU)且需要抗组胺药治疗和短期使用皮质类固醇的患者,应考虑使用环孢素A(CsA)。据报道,在这类患者中,给予CsA 1 - 3个月(3mg/kg/天),三分之二的患者可实现完全缓解,持续3 - 6个月,四分之一的患者可实现长期完全缓解。

目的

研究长期使用CsA治疗对严重CU患者的有益效果、安全性和副作用,这些患者此前仅实现了短期缓解。

方法

六名严重CU患者(平均年龄40.8岁±11.9)(病程7.3年±6.2)仍接受CsA(2 - 3mg/kg/天)治疗,为期11.6年±4年。

结果

五名患者通过CsA治疗病情得到良好控制,无需额外治疗。一名患者需要加用5 - 10mg/天的泼尼松(同时继续使用3mg/kg/天的CsA)以减轻荨麻疹的严重程度。两名患者抱怨有轻度多毛症和周围神经病变,一名患者抱怨有非常轻微的腹泻。

结论

长期使用CsA治疗有利于维持严重CU患者的缓解状态。它无需使用皮质类固醇,且副作用轻微。需要更多患者的进一步经验来强化我们的发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验